Acadia Pharmaceutica (ACAD) 37.23 $ACAD ACADIA

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acadia Pharmaceutica (ACAD) 37.23 $ACAD

ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016
BusinessWire - Fri Jul 29, 5:15PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2016 on Thursday, August 4, 2016, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Thursday, August 4, 2016, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and operations.
ACAD: 37.23 (+0.19)

Learn how to target a 20% return on Tesla Motors, or get option-trade ideas on Opko Health, Activision Blizzard, Smith & Wesson and ACADIA Pharmaceuticals or any stock you choose
PR Newswire - Mon Jul 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA OPK ATVI SWHC ACAD.
TSLA: 230.01 (-4.78), ATVI: 40.07 (-0.09), ACAD: 37.23 (+0.19), OPK: 10.07 (+0.12), SWHC: 30.36 (+0.91)

Facebook trade offers a 30% return in 32 days, or find similar option trades on ACADIA Pharmaceuticals, Perrigo Co., Jabil Circuit, and SolarCity
PR Newswire - Mon Jul 18, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACAD, FB, JBL, PRGO, and SCTY.
PRGO: 91.10 (-0.29), ACAD: 37.23 (+0.19), SCTY: 24.72 (-1.98), FB: 124.31 (+0.37), JBL: 20.43 (+0.08)

Look for Shares of Acadia Pharmaceuticals to Potentially Rebound after Yesterday's 4.41% Sell Off
Comtex SmarTrend(R) - Wed Jul 13, 1:01PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $32.80 to a high of $35.02. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $33.05 on volume of 884,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 37.23 (+0.19)

ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
BusinessWire - Thu Jun 16, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, at 9:00 a.m. Eastern Time in New York City.
ACAD: 37.23 (+0.19)

20.3% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Thu Jun 09, 1:42PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 20th, 2016 at $33.51. In approximately 3 weeks, Acadia Pharmaceuticals has returned 20.27% as of today's recent price of $40.30.
ACAD: 37.23 (+0.19)

Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 64.08 (+0.09), ACAD: 37.23 (+0.19), OPK: 10.07 (+0.12), CLDX: 4.67 (+0.05)

Watch for Acadia Pharmaceuticals to Potentially Pullback After Gaining 8.48% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 2:01PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $36.48 to a high of $39.31. Yesterday, the shares gained 8.5%, which took the trading range above the 3-day high of $36.88 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 37.23 (+0.19)

Acadia Pharmaceuticals Rises 2.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 1:21PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $35.40 to a high of $36.88. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $36.40 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 37.23 (+0.19)

ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016
BusinessWire - Wed Jun 01, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016, at 3:20 p.m. Pacific Time in Rancho Palos Verdes, California.
ACAD: 37.23 (+0.19)

ACADIA Pharmaceuticals Announces NUPLAZID(TM) (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson's Disease Psychosis
BusinessWire - Tue May 31, 7:00AM CDT
--An Estimated 40 Percent of Parkinson's Disease Patients Have Psychosis
ACAD: 37.23 (+0.19)

Bellicum Appoints Jim Daly to its Board of Directors
BusinessWire - Wed May 18, 6:00AM CDT
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Jim Daly to its Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of ACADIA Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc.
ACAD: 37.23 (+0.19), BLCM: 16.04 (+0.16), CMRX: 4.08 (+0.09)

Acadia Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 5.56%
Comtex SmarTrend(R) - Tue May 17, 2:12PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $29.90 to a high of $32.72. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $30.18 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 37.23 (+0.19)

Acadia reports 1Q loss
Automated Insights - Thu May 05, 4:44PM CDT
SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Thursday reported a loss of $49.8 million in its first quarter.
ACAD: 37.23 (+0.19)

ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 3:05PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2016.
ACAD: 37.23 (+0.19)

ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
BusinessWire - Wed May 04, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 11, 2016, at 2:20 p.m. Pacific Time in Las Vegas.
ACAD: 37.23 (+0.19)

Why ACADIA Pharmaceuticals Inc Jumped 12.7% in April
Brian Feroldi, The Motley Fool - Motley Fool - Wed May 04, 7:22AM CDT
PHOTO CREDIT: ACADIA PHARMACEUTICALS  What: Investors in ACADIA Pharmaceuticals   had another great month: The central nervous system-focused biopharma's shares tacked on another 12.7%, according to data from  S&P Global Market...
ACAD: 37.23 (+0.19)

Acadia Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 3.53%
Comtex SmarTrend(R) - Mon May 02, 12:35PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $30.58 to a high of $34.25. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $31.00 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 37.23 (+0.19)

Weekly Biotech Update from Market Exclusive Covering - Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), Kempharm Inc. (NASDAQ:KMPH), Pfizer Inc. (NYSEFE), Sarepta Therapeutics Inc (NASDAQ:SRPT), Collegium Pharmaceutical Inc. (NASDAQ:COLL),
ACCESSWIRE - Mon May 02, 7:12AM CDT
NEW YORK, NY / ACCESSWIRE / May 2, 2016 / Market Exclusive Weekly Biotech Report including:
ACAD: 37.23 (+0.19), KMPH: 4.31 (+0.09), SRPT: 25.91 (+0.63), PFE: 37.31 (+0.42), COLL: 11.86 (-0.27)

3 All-or-Nothing Stocks To Watch Closely
Tyler Crowe, Evan Niu, CFA, and Brian Feroldi, The Motley Fool - Motley Fool - Sat Apr 30, 7:02AM CDT
Image source: Pixabay . Some companies are pretty easy to understand because their entire future is predicated on one thing happening. These all-or-nothing stocks can be very lucrative investments if that one thing goes the right way for them, but...
TSLA: 230.01 (-4.78), ACAD: 37.23 (+0.19), DNR: 2.72 (-0.18)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 156

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 129

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 156

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 199

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 111

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 171

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 85

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 41

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 277

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading

Top 5 Most Recently Viewed Articles

Olo Inc. Under Investigation for Potential Fiduciary Violations

Updated Category News Views 255

Olo Inc. Faces Investigation Over Fiduciary Duties Olo Inc. is currently under investigation by legal authorities due to possible breaches of fiduciary duty by its directors and management. This scrutiny follows Olo's announcement regarding a major acquisition deal with investment firm Thoma Bravo, valued at around $2 billion. Details of the Investigation The focus of the...

Continue Reading
Join MT Højgaard Holding's Conference Call on FY 2024 Results

Updated Category News Views 115

MT Højgaard Holding A/S Conference Call Overview MT Højgaard Holding is set to release its annual report for the fiscal year 2024 on a chosen date. Following this release, a conference call will take place where the management team will delve into the company’s performance and projections for the future. This session aims to provide insights into the results for the...

Continue Reading
ClearValue Consulting Partners with Restb.ai for Advanced Appraisals

Updated Category News Views 77

Unlocking Efficiency in Appraisal Reviews ClearValue Consulting, a leader in innovative valuation solutions, has announced an exciting new partnership with Restb.ai, a prominent name in AI-powered computer vision. This collaboration is set to redefine the appraisal review landscape, bringing in advanced technologies to streamline processes and enhance quality. The Impact...

Continue Reading
BrightSphere's Transformation: New Name and Leadership Direction

Updated Category News Views 393

BrightSphere Investment Group Inc. (NYSE: BSIG) announced its rebranding to Acadian Asset Management back in early 2025, marking a major shift in strategy. This wasn't just a name change; it was the end of their multi-boutique model and the start of a more streamlined focus on asset management. They offloaded six out of seven affiliates to zero in on core...

Continue Reading
Why Super Micro Computer’s Growth Could Still Continue

Updated Category News Views 339

Super Micro Computer (NASDAQ: SMCI) kicked off 2024 like a rocket, watching its stock explode by an eye-popping 188% in the first half. It was a remarkable performance that even left tech giants scrambling for a second look. The surge stemmed largely from surging demand for their cutting-edge workstations and servers—essential cogs in the booming artificial intelligence...

Continue Reading